Title of article :
Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients
Author/Authors :
Movahedi ، Mahshid Division of Allergy and Clinical Immunology - Pediatrics Center of Excellence, Children’s Medical Center Hospital - Tehran University of Medical Sciences , Movahedi ، Masoud , Parvaneh ، Nima Division of Allergy and Clinical Immunology - Pediatrics Center of Excellence, Children’s Medical Center Hospital - Tehran University of Medical Sciences , Abolhassani ، Hassan Division of Immunology, Department of Medical Biochemistry and Biophysics - Karolinska Institute Stockholm , Mahdavi ، Mohadese Division of Allergy and Clinical Immunology - Pediatrics Center of Excellence, Children’s Medical Center - Tehran University of Medical Sciences , Mosavikhorshidi ، Mohadese Division of Allergy and Clinical Immunology - Pediatrics Center of Excellence, Children’s Medical Center Hospital - Tehran University of Medical Sciences , Alizadeh ، Fatemeh Division of Allergy and Clinical Immunology - Pediatrics Center of Excellence, Children’s Medical Center - Tehran University of Medical Sciences , Shokri ، Mehdi Department of Pediatrics - Faculty of Medicine - Ilam University of Medical Sciences , Kalantari ، Arash Department of Immunology and Allergy - Imam Khomeini Hospital Complex - Tehran University of Medical Sciences
Abstract :
Patients with inborn errors of immunity (IEI) are among the high-risk groups regarding COVID-19. Receiving booster doses (third and fourth) in addition to the standard doses is recommended in these patients. This study investigated the antibody response before and after a booster dose of Sinopharm vaccine in IEI patients. Thirty patients ( 12 years) with antibody deficiencies, referred to Imam Khomeini Hospital and Children s Medical Center in Tehran, were enrolled in this prospective cross-sectional study. All patients were fully vaccinated with the BBIBP-CorV vaccine (2 doses of Sinopharm). Initial measurements of anti-receptor-binding domain (anti-RBD) and anti-nucleocapsid (anti-N) IgG antibody responses were conducted by enzyme-linked immunosorbent assay (ELISA). Subsequently, all patients received a booster dose of the vaccine. Four to six weeks after booster injection, the levels of antibodies were re-evaluated. Twenty patients with common variable immunodeficiency (CVID), 7 cases with agammaglobulinemia and 3 patients with hyper IgM syndrome were studied. Anti-RBD IgG and anti-N IgG antibodies increased in all patients after the booster. Our results indicated the need of receiving booster doses of the COVID-19 vaccine in patients with antibody deficiencies, even for enhancing humoral immune response specially in patients with CVID.
Keywords :
Antibody deficiency , Booster , COVID , 19 , Inborn errors of immunity , Primary immunodeficiency , Sinopharm vaccine , Vaccination
Journal title :
Iranian Journal of Allergy, Asthma and Immunology
Journal title :
Iranian Journal of Allergy, Asthma and Immunology
